The impact of DeltaG on the oral bioavailability of low bioavailable therapeutic agents.
Salama
Noha N
NN
Pharmacokinetics-Biopharmaceutics Laboratory, Department of Pharmaceutical Sciences, School of Pharmacy, University of Maryland at Baltimore, 20 Penn Street, Baltimore, MD 21201, USA.
Fasano
Alessio
A
Thakar
Manjusha
M
Eddington
Natalie D
ND
D000212:Acyclovir / Q000493:pharmacokinetics*; D000818:Animals; D000998:Antiviral Agents / Q000493:pharmacokinetics; D001682:Biological Availability; D002772:Cholera Toxin / Q000378:metabolism; D004731:Endotoxins; D004734:Energy Metabolism; D006801:Humans; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley
D000998:Antiviral Agents; D004731:Endotoxins; C077728:zonula occludens toxin, Vibrio cholerae; D002772:Cholera Toxin; D000212:Acyclovir